Clinical Study on the Effects of Pulmonary Vessels on Cryoablation and Preventive Embolization Strategies

ConditionLung Cancer
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorHaibo Shao

About this trial

This study targeted high-risk individuals with incomplete ablation and performed selective pulmonary artery embolization before lung cryoablation, which could enhance the therapeutic effect and reduce the risk of intraoperative bleeding. Previous studies have shown that selective pulmonary artery embolization before ablation has no adverse reactions related to embolization. In this study, gelatin sponge particles were used for selective pulmonary artery embolization. Gelatin sponge is an absorbable embolic material that can be absorbed and degraded in the human body within about 7 days, which has high safety and a low probability of adverse reactions. The surgical risks are detailed in the surgical protocol. The study aims to optimize the lung cryoablation strategy for high-risk individuals with incomplete ablation, aiming to improve the prognosis of high-risk recurrent patients. The two groups of patients underwent lung CT reexamination every three months after surgery to observe the tumor ablation situation.

Eligibility criteria

Qualifiers

Individuals at high risk of incomplete ablation (for example, there are vessels with a diameter greater than 3mm within 1cm around the pulmonary nodule);

Scheduled for lung cryoablation, meeting the surgical indications and without any specific contraindications;

The long diameter of the lung tumor is less than 3cm;

The single cryoablation needle will be used. -

Disqualifiers

Postoperative complications such as massive pneumothorax and bleeding occurred, which affected the observation of the ice ball's shape;

Poor image quality or incomplete images. -

Trial design

Treatments tested in this trial

  • Pulmonary artery embolization

Treatment groups

20 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Haibo Shao

Lead sponsor

First Hospital of China Medical University

Sponsor institution